Recent Updates
Recently added Catalysts

L-756423

Phase 2

HIV Infections | Small molecule | Infectious Disease |Merck & Company, Inc.|Last Updated: Jun 24, 2005

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment30
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00002452A Study on the Safety and Effectiveness of L-756423 Plus Indinavir in HIV-Positive Patients Who Have Previously Taken IndinavirPHASE2 COMPLETED 30 - -Jun 24, 20058 United States
Unlock Drug Trial Details
Study Design & Arms
PurposeTREATMENT
Interventions
NameTypeDescription
L-756423DRUG -
Indinavir sulfateDRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites8

Inclusion Criteria You may be eligible for this study if you: * Are HIV-positive. * Are at least 18 years old. * Have a viral load of at least 1,000 copies/ml. * Have a CD4 cell count of at least 100 cells/mm3. * Have experienced treatment failure (your viral load increased significantly) within 2...

Countries:United States
Unlock Eligibility Criteria